Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), sold 7,175 shares at $0.55 ($4K) on 2024-10-03, disclosed to the SEC on 2024-10-03.
Scheduled sale ($4k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |